Start here if you're new
what it is
Contineum is trying to turn lab-made pills into treatments for brain and lung diseases.
how it gets paid
Last year Contineum Therap made $0 in revenue.
what just happened
Revenue stayed at $0, and EPS came in at -$1.61.
At a glance
n/a balance sheet
18.2% ROC on screen — ignore next to $0 revenue; ratio is not an operating return
-$2.18 fy2024 eps est
$50M rev est is stale vs $0 actual—treat as vendor noise
operating margin n/m at $0 product revenue
What they do
Contineum is trying to turn lab-made pills into treatments for brain and lung diseases.
You are backing 41 employees against a ~$485M market cap. The 40-patient Phase 2 setup called out on-page is for PIPE-791 (IPF), not PIPE-307—keep readouts attached to the right asset. The edge is focus: two main programs, one not-yet-in-people side bet, and no sales machine to distract the team.
How they make money
$0
annual revenue
The products that matter
LPA1R antagonist for IPF
PIPE-791
lead program · Phase 2 setup in 2026
This is the lead asset. Management has pointed to a 40-patient Phase 2 trial in idiopathic pulmonary fibrosis starting in 2026, so your near-term thesis runs through this readout path.
40-patient study
M1R antagonist for MS relapse
PIPE-307
second core asset · high dependency
This is the other half of the story. The company has disclosed high dependency on PIPE-307 and PIPE-791, which is corporate language for saying most of the equity value sits in two programs.
two-asset story
cash that funds the pipeline
Balance sheet runway
$175M cash · $47M annual burn
Not a drug, but it matters like one. With $175M in cash and $47M burned over the last year, the balance sheet gives you time to wait for data — and tells you when dilution risk moves from background noise to headline.
~3.7 years
Key numbers
$0
annual revenue
You are buying a story, not a sales stream.
$4M
long-term debt
Debt is tiny next to a $485 million market cap, so leverage is not the threat.
41
employees
A 41-person team has little room for a bad trial.
18.2%
return on capital
VL says each dollar tied up earns 18.2 cents on paper. That is a weird number for a company with $0 revenue.
Financial health
n/a
strength
- balance sheet grade n/a
- long-term debt $4M (1% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for CTNM right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue stayed at $0, and EPS came in at -$1.61.
The strip’s ~-$2.18 is FY2024 EPS est.; the -$1.61 here is a quarterly print in this feed—do not read them as the same period or a clean “smaller FY loss” without the filing. The business is still a clinical-stage bill, not a sales engine.
$0
revenue
-$1.61
eps
n/a
n/a
revenue
Revenue was $0 again. That matters because the stock has no sales floor, only trial expectations.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is clinical failure or delay in PIPE-791 and PIPE-307. CTNM has no approved products to absorb bad data.
med
two-asset dependency
Management has disclosed high dependency on PIPE-791 and PIPE-307. That is unusually direct language, and it tells you most of the equity story sits in two programs.
With zero product revenue today, failed data would not pressure a business line. It would pressure the entire valuation.
med
cash burn rising faster than expected
The company burned $47M over the last year against $175M of cash. That supports a roughly 3.7-year runway if spending holds near recent levels. Clinical expansion rarely makes spending go down.
If burn accelerates, the runway shortens and the market starts pricing the next capital raise long before the cash is gone.
med
ATM usage can cap upside
The at-the-market program was increased to $100M in March 2026. That gives management optional financing, but it also creates a standing reminder that new shares can arrive if the window is open.
The authorization is about 21% of the current $485M market cap. Even partial use matters when the company has no operating cash flow to offset it.
A forced raise or weak trial outcome would hit a company with zero product revenue and only two real shots on goal.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical
PIPE-791 Phase 2 start and enrollment pace
The 40-patient IPF study expected to start in 2026 is the clearest catalyst on the page. Start dates matter. Enrollment speed matters more.
runway
cash burn versus the $47M recent pace
If spending starts moving well above the last twelve months, your roughly 3.7-year runway math stops being comforting.
dilution
whether the $100M ATM actually gets used
The authorization exists. What matters next is cadence. Opportunistic use is one thing. Reliance is another.
sentiment
the stock staying near the top of its $3–$16 range
At $15.34, expectations are not depressed. Good news still helps, but disappointment from near highs usually lands harder.
Analyst rankings
coverage depth
thin
Institutional ranking data is limited for CTNM, which usually happens in smaller pre-revenue biotech names where the stock trades more on catalysts than on broad screen factors.
source: institutional data
Institutional activity
institutional ownership data for CTNM is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$15
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive